Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Standard

Poor drug distribution as a possible explanation for the results of the PRECISE trial. / Sampson, John H; Archer, Gary; Pedain, Christoph; Wembacher-Schröder, Eva; Westphal, Manfred; Kunwar, Sandeep; Vogelbaum, Michael A; Coan, April; Herndon, James E; Raghu, Raghavan; Brady, Martin L; Reardon, David A; Friedman, Allan H; Friedman, Henry S; Rodríguez-Ponce, M Inmaculada; Chang, Susan M; Mittermeyer, Stephan; Croteau, David; Puri, Raj K.

In: J NEUROSURG, 2009.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Sampson, JH, Archer, G, Pedain, C, Wembacher-Schröder, E, Westphal, M, Kunwar, S, Vogelbaum, MA, Coan, A, Herndon, JE, Raghu, R, Brady, ML, Reardon, DA, Friedman, AH, Friedman, HS, Rodríguez-Ponce, MI, Chang, SM, Mittermeyer, S, Croteau, D & Puri, RK 2009, 'Poor drug distribution as a possible explanation for the results of the PRECISE trial.', J NEUROSURG. <http://www.ncbi.nlm.nih.gov/pubmed/20020841?dopt=Citation>

APA

Sampson, J. H., Archer, G., Pedain, C., Wembacher-Schröder, E., Westphal, M., Kunwar, S., Vogelbaum, M. A., Coan, A., Herndon, J. E., Raghu, R., Brady, M. L., Reardon, D. A., Friedman, A. H., Friedman, H. S., Rodríguez-Ponce, M. I., Chang, S. M., Mittermeyer, S., Croteau, D., & Puri, R. K. (2009). Poor drug distribution as a possible explanation for the results of the PRECISE trial. J NEUROSURG. http://www.ncbi.nlm.nih.gov/pubmed/20020841?dopt=Citation

Vancouver

Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J NEUROSURG. 2009.

Bibtex

@article{c51077c928844b3ab1a290c820d8fe3b,
title = "Poor drug distribution as a possible explanation for the results of the PRECISE trial.",
abstract = "Object Convection-enhanced delivery (CED) is a novel intracerebral drug delivery technique with considerable promise for delivering therapeutic agents throughout the CNS. Despite this promise, Phase III clinical trials employing CED have failed to meet clinical end points. Although this may be due to inactive agents or a failure to rigorously validate drug targets, the authors have previously demonstrated that catheter positioning plays a major role in drug distribution using this technique. The purpose of the present work was to retrospectively analyze the expected drug distribution based on catheter positioning data available from the CED arm of the PRECISE trial. Methods Data on catheter positioning from all patients randomized to the CED arm of the PRECISE trial were available for analyses. BrainLAB iPlan Flow software was used to estimate the expected drug distribution. Results Only 49.8% of catheters met all positioning criteria. Still, catheter positioning score (hazard ratio 0.93, p = 0.043) and the number of optimally positioned catheters (hazard ratio 0.72, p = 0.038) had a significant effect on progression-free survival. Estimated coverage of relevant target volumes was low, however, with only 20.1% of the 2-cm penumbra surrounding the resection cavity covered on average. Although tumor location and resection cavity volume had no effect on coverage volume, estimations of drug delivery to relevant target volumes did correlate well with catheter score (p <0.003), and optimally positioned catheters had larger coverage volumes (p <0.002). Only overall survival (p = 0.006) was higher for investigators considered experienced after adjusting for patient age and Karnofsky Performance Scale score. Conclusions The potential efficacy of drugs delivered by CED may be severely constrained by ineffective delivery in many patients. Routine use of software algorithms and alternative catheter designs and infusion parameters may improve the efficacy of drugs delivered by CED.",
author = "Sampson, {John H} and Gary Archer and Christoph Pedain and Eva Wembacher-Schr{\"o}der and Manfred Westphal and Sandeep Kunwar and Vogelbaum, {Michael A} and April Coan and Herndon, {James E} and Raghavan Raghu and Brady, {Martin L} and Reardon, {David A} and Friedman, {Allan H} and Friedman, {Henry S} and Rodr{\'i}guez-Ponce, {M Inmaculada} and Chang, {Susan M} and Stephan Mittermeyer and David Croteau and Puri, {Raj K}",
year = "2009",
language = "Deutsch",
journal = "J NEUROSURG",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",

}

RIS

TY - JOUR

T1 - Poor drug distribution as a possible explanation for the results of the PRECISE trial.

AU - Sampson, John H

AU - Archer, Gary

AU - Pedain, Christoph

AU - Wembacher-Schröder, Eva

AU - Westphal, Manfred

AU - Kunwar, Sandeep

AU - Vogelbaum, Michael A

AU - Coan, April

AU - Herndon, James E

AU - Raghu, Raghavan

AU - Brady, Martin L

AU - Reardon, David A

AU - Friedman, Allan H

AU - Friedman, Henry S

AU - Rodríguez-Ponce, M Inmaculada

AU - Chang, Susan M

AU - Mittermeyer, Stephan

AU - Croteau, David

AU - Puri, Raj K

PY - 2009

Y1 - 2009

N2 - Object Convection-enhanced delivery (CED) is a novel intracerebral drug delivery technique with considerable promise for delivering therapeutic agents throughout the CNS. Despite this promise, Phase III clinical trials employing CED have failed to meet clinical end points. Although this may be due to inactive agents or a failure to rigorously validate drug targets, the authors have previously demonstrated that catheter positioning plays a major role in drug distribution using this technique. The purpose of the present work was to retrospectively analyze the expected drug distribution based on catheter positioning data available from the CED arm of the PRECISE trial. Methods Data on catheter positioning from all patients randomized to the CED arm of the PRECISE trial were available for analyses. BrainLAB iPlan Flow software was used to estimate the expected drug distribution. Results Only 49.8% of catheters met all positioning criteria. Still, catheter positioning score (hazard ratio 0.93, p = 0.043) and the number of optimally positioned catheters (hazard ratio 0.72, p = 0.038) had a significant effect on progression-free survival. Estimated coverage of relevant target volumes was low, however, with only 20.1% of the 2-cm penumbra surrounding the resection cavity covered on average. Although tumor location and resection cavity volume had no effect on coverage volume, estimations of drug delivery to relevant target volumes did correlate well with catheter score (p <0.003), and optimally positioned catheters had larger coverage volumes (p <0.002). Only overall survival (p = 0.006) was higher for investigators considered experienced after adjusting for patient age and Karnofsky Performance Scale score. Conclusions The potential efficacy of drugs delivered by CED may be severely constrained by ineffective delivery in many patients. Routine use of software algorithms and alternative catheter designs and infusion parameters may improve the efficacy of drugs delivered by CED.

AB - Object Convection-enhanced delivery (CED) is a novel intracerebral drug delivery technique with considerable promise for delivering therapeutic agents throughout the CNS. Despite this promise, Phase III clinical trials employing CED have failed to meet clinical end points. Although this may be due to inactive agents or a failure to rigorously validate drug targets, the authors have previously demonstrated that catheter positioning plays a major role in drug distribution using this technique. The purpose of the present work was to retrospectively analyze the expected drug distribution based on catheter positioning data available from the CED arm of the PRECISE trial. Methods Data on catheter positioning from all patients randomized to the CED arm of the PRECISE trial were available for analyses. BrainLAB iPlan Flow software was used to estimate the expected drug distribution. Results Only 49.8% of catheters met all positioning criteria. Still, catheter positioning score (hazard ratio 0.93, p = 0.043) and the number of optimally positioned catheters (hazard ratio 0.72, p = 0.038) had a significant effect on progression-free survival. Estimated coverage of relevant target volumes was low, however, with only 20.1% of the 2-cm penumbra surrounding the resection cavity covered on average. Although tumor location and resection cavity volume had no effect on coverage volume, estimations of drug delivery to relevant target volumes did correlate well with catheter score (p <0.003), and optimally positioned catheters had larger coverage volumes (p <0.002). Only overall survival (p = 0.006) was higher for investigators considered experienced after adjusting for patient age and Karnofsky Performance Scale score. Conclusions The potential efficacy of drugs delivered by CED may be severely constrained by ineffective delivery in many patients. Routine use of software algorithms and alternative catheter designs and infusion parameters may improve the efficacy of drugs delivered by CED.

M3 - SCORING: Zeitschriftenaufsatz

JO - J NEUROSURG

JF - J NEUROSURG

SN - 0022-3085

ER -